Macular Translocation Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Macular translocation surgery (MTS) is an advanced vitreoretinal procedure in which the macula — the central, high-acuity zone of the retina responsible for detailed and colour vision — is surgically detached and repositioned over a healthier area of the retinal pigment epithelium (RPE). The technique was developed to rescue central vision in patients with subfoveal choroidal neovascular membranes (CNVMs) that cannot be treated safely with conventional laser photocoagulation without destroying the fovea itself.

The central concept is straightforward: when the retinal tissue beneath the macula is irreversibly damaged by abnormal blood vessel growth, moving the macula to an area of intact RPE can allow the photoreceptors to continue functioning. Two principal surgical variants have been refined over the past three decades:

• Limited Macular Translocation (LMT): The retina is partially detached and buckled using a scleral imbrication technique, shifting the fovea by 800–1,500 µm. A lesser degree of iatrogenic cyclotorsion occurs, which is corrected with extraocular muscle surgery.
• Full Macular Translocation (FMT) with 360-degree retinotomy: The entire retina is detached from the RPE via a complete circumferential retinotomy, allowing a larger shift (up to 3,000–4,500 µm) before the retina is reattached with silicone oil tamponade. This technique offers a greater translocation distance but carries a higher complication profile.

With the widespread adoption of anti-VEGF (vascular endothelial growth factor) agents — ranibizumab, bevacizumab, and aflibercept — the indications for macular translocation have become more selective. However, MTS remains a viable surgical option for eyes with large subfoveal membranes, cases refractory to anti-VEGF therapy, or situations where anti-VEGF treatment is contraindicated.

Macular translocation surgery is performed primarily for conditions involving subfoveal damage to the RPE that threaten central vision:

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD): The most common indication. Subfoveal CNVMs erode the RPE–photoreceptor complex. MTS is considered when the neovascular membrane is large (>4 disc areas), predominantly classic in fluorescein angiography, or when anti-VEGF therapy has failed or cannot be sustained.
• Myopic Choroidal Neovascularization: Pathological myopia (>6 diopters) can cause ruptures in Bruch's membrane and subfoveal CNVMs in younger patients who cannot sustain years of anti-VEGF injections. MTS offers a one-time surgical alternative.
• Idiopathic Subfoveal CNVMs: Occurring in younger adults without identifiable systemic disease, these membranes sometimes recur after photodynamic therapy or anti-VEGF, making translocation a consideration.
• Choroidal Neovascularization Secondary to Ocular Histoplasmosis Syndrome (OHS): A fungal infection endemic in river valleys of North America that can produce aggressive subfoveal membranes in young patients.
• Central Serous Chorioretinopathy (CSC) with secondary CNV: Chronic CSC can lead to secondary neovascularisation that threatens foveal integrity.

Careful patient selection is critical for achieving favourable outcomes. Ophthalmologists and vitreoretinal surgeons evaluate the following criteria:

Favourable Candidates

• Best-corrected visual acuity (BCVA) of 20/200 or better in the affected eye — sufficient photoreceptor viability to benefit from repositioning
• Subfoveal CNVM with a classic or predominantly classic angiographic pattern on fluorescein angiography (FA) or OCT-angiography
• Absence of extensive outer retinal or photoreceptor layer loss on spectral-domain OCT
• Failure or intolerance of at least 3–6 monthly anti-VEGF injections
• Age <80 years with adequate systemic health to tolerate 2–4 hours of general or retrobulbar anaesthesia
• Willingness and ability to comply with strict post-operative face-down positioning for 1–2 weeks (FMT technique)

Contraindications

• Predominantly occult or fibrotic CNVM with poor likelihood of photoreceptor recovery
• Dense foveal scarring or disciform scar formation
• Only-seeing eye (relative contraindication — extreme caution required)
• Uncontrolled systemic hypertension, severe coagulopathy, or inability to undergo anaesthesia
• Advanced glaucoma or other co-existing optic neuropathy

Pre-operative evaluation should include FA, indocyanine green angiography (ICGA), spectral-domain OCT with en-face imaging, and OCT-angiography to delineate the CNVM accurately and assess RPE integrity at the proposed landing zone.

The choice between surgical techniques depends on CNVM size, patient factors, and surgeon expertise:

1. Limited Macular Translocation (LMT)

A scleral shortening (imbrication) or relaxing retinotomy technique is used to create a peripheral retinal detachment. The macula shifts 800–1,500 µm inferiorly or supero-temporally, placing the fovea over undamaged RPE. The procedure avoids full retinotomy and silicone oil, reducing the risk of proliferative vitreoretinopathy (PVR). However, the degree of translocation is limited. Post-operative cyclotorsion (image tilt) is corrected by inferior oblique myectomy or superior oblique tenotomy at a second stage.

2. Full Macular Translocation (FMT) with 360-degree Retinotomy

Following a complete vitrectomy, the retina is detached over its entire extent via a 360-degree peripheral retinotomy. This allows the macula to be shifted up to 3,000–4,500 µm — enough to clear most large subfoveal membranes. Silicone oil is injected to flatten and support the repositioned retina. The underlying CNVM is then treated with direct subretinal injection of tissue plasminogen activator (tPA) or laser photocoagulation applied through the translucent peripheral retina. Silicone oil removal occurs at 2–3 months post-operatively. Cyclotorsion correction surgery is required as a staged procedure.

3. Combined Macular Translocation with Subretinal Surgery

In select cases, subretinal excision of the neovascular membrane is performed alongside translocation. A small retinotomy is made, and the CNVM is removed with specially designed subretinal instruments. This approach carries higher risk of RPE and photoreceptor damage but may be considered for large Type 1 (subretinal) membranes.

4. Adjunctive Treatments

Post-translocation anti-VEGF injections or photodynamic therapy (PDT) may be administered if residual or recurrent neovascularization is detected at the new foveal location, emphasising the need for long-term surveillance with OCT-angiography.

Published series and systematic reviews document the following potential benefits of macular translocation surgery:

• Vision Stabilization or Improvement: In carefully selected patients, 40–60% achieve visual stability or gain ≥2 lines of BCVA on the Snellen chart at 12–24 months post-operatively. The Macular Translocation with 360° Retinotomy (MT360) Study reported a mean gain of 2.9 lines in successful cases.
• Single Intervention Potential: Unlike anti-VEGF therapy requiring monthly or bi-monthly injections indefinitely, MTS offers the possibility of durable treatment in a single surgical session, reducing the long-term burden of intravitreal injections.
• Foveal Repositioning over Healthy RPE: Moving the fovea to intact RPE can support photoreceptor metabolism and signal transduction, preserving remaining cone function.
• CNVM Control: Surgical excision or laser ablation of the CNVM at the time of surgery eliminates or reduces the neovascular drive, particularly valuable in younger patients with myopic CNV who face decades of potential recurrence.
• Quality of Life: Studies using the VFQ-25 (Visual Function Questionnaire) demonstrate significant improvements in near-vision tasks, reading ability, and independence in patients with successful translocation.

Macular translocation is among the most technically demanding vitreoretinal procedures, and patients must be counselled thoroughly about significant complication risks:

Intraoperative Risks

• Retinal Tear or Giant Retinal Tear: Particularly during the retinotomy phase of FMT; occurs in 5–15% of cases.
• Subretinal or Suprachoroidal Haemorrhage: Especially when operating on active CNVMs with friable vessels.
• Photoreceptor Damage: Direct trauma to photoreceptors during detachment or reattachment can reduce the functional benefit.

Post-operative Risks

• Proliferative Vitreoretinopathy (PVR): The most feared complication; occurs in 10–25% of FMT cases and can cause tractional retinal detachment requiring revision surgery.
• Retinal Detachment: Either rhegmatogenous (from residual tears) or tractional; reported in 10–20% of cases.
• Cyclotorsion and Diplopia: Nearly universal after FMT; image tilt of 20–45 degrees requires correction with strabismus surgery and prismatic glasses.
• Macular Pucker (Epiretinal Membrane): Seen in 15–30% of cases post-surgery, potentially reducing gained visual acuity.
• Cataract Formation: Accelerated by vitrectomy, silicone oil tamponade, and intraocular inflammation; occurs in the majority of phakic patients within 12–18 months.
• Recurrent Choroidal Neovascularization: New CNVM can develop at the new foveal location, requiring anti-VEGF treatment.
• Silicone Oil Complications: Emulsification, elevated intraocular pressure, and band keratopathy (FMT only).

Overall anatomical success (attached retina) is achieved in approximately 70–80% of cases at one year; functional success (visual improvement) occurs in a smaller proportion. Patients should discuss realistic expectations with their vitreoretinal surgeon prior to proceeding.

Post-operative management is intensive and requires close monitoring:

Immediate Post-operative Period (Days 1–14)

• For FMT with silicone oil: strict face-down positioning for 7–14 days is mandatory to allow the retina to settle against the RPE at the new foveal location. Failure to maintain positioning significantly increases the risk of retinal detachment.
• For LMT: less restrictive positioning; patients may be ambulatory within 24–48 hours.
• Topical antibiotics, corticosteroids, and cycloplegic drops are prescribed to reduce inflammation and prevent infection.
• Intraocular pressure monitoring every 24–48 hours during the first week.

Early Follow-up (Weeks 2–12)

• Slit-lamp and fundus examination at 1, 2, 4, and 8 weeks post-operatively.
• OCT imaging to assess retinal attachment status, sub-retinal fluid, and foveal contour.
• Strabismus surgery (inferior oblique myectomy or superior oblique tenotomy) is typically planned at 6–8 weeks to correct cyclotorsion.
• Silicone oil removal surgery at 2–3 months (FMT cases).

Long-term Monitoring (3 Months–2 Years)

• BCVA and microperimetry assessments every 3–6 months to track functional outcomes.
• OCT-angiography every 6 months to detect recurrent CNV at the new foveal site.
• Cataract surgery referral if lens opacity progresses to visually significant levels (usually within 12–24 months of vitrectomy).
• Ongoing anti-VEGF injections if recurrent neovascularization is detected.

Macular translocation surgery is a technically demanding, highly specialised procedure. Costs vary considerably by country, centre, and technique used:

• Surgical Technique: FMT with 360-degree retinotomy is significantly more complex and expensive than LMT due to the need for silicone oil tamponade, extended operating time, and staged strabismus correction surgery.
• Hospital and Operating Theatre Fees: Use of specialised vitreoretinal operating equipment, wide-angle viewing systems (BIOM/EIBOS), and high-end vitrectomy machines increases facility costs.
• Surgeon Expertise: Vitreoretinal surgeons who perform this complex procedure are few in number; their fees reflect specialised training and low surgical volume.
• Silicone Oil Removal: A second operating theatre visit for silicone oil removal (FMT) adds to total treatment costs.
• Strabismus Correction Surgery: A third procedure (cyclotorsion correction) is typically performed as a staged operation.
• Post-operative Medications and Imaging: Extended use of OCT, OCT-angiography, anti-VEGF injections, and specialist visits contribute to overall costs.
• Geographic Variation: Costs in India, Thailand, Turkey, and Hungary are typically 40–65% lower than equivalent care in the US, UK, or Australia while maintaining international accreditation standards.

Patients seeking macular translocation abroad should ensure the operating surgeon has documented experience with at least 30–50 MTS cases and that the centre has vitreoretinal ICU capabilities and 24-hour ophthalmic emergency cover.

With the advent of effective pharmacological agents, macular translocation is now one of several treatment options for subfoveal CNVMs. Alternatives include:

• Anti-VEGF Intravitreal Injections (First-line Standard of Care): Ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea), and faricimab (Vabysmo) are administered monthly or bi-monthly. The ANCHOR and MARINA trials demonstrated that 90–95% of treated eyes maintain or improve vision. Anti-VEGF therapy has largely replaced macular translocation as first-line treatment.
• Photodynamic Therapy (PDT) with Verteporfin: Selectively destroys CNVMs using a photosensitizing drug activated by non-thermal laser. Effective for predominantly classic CNVMs and remains useful for polypoidal choroidal vasculopathy (PCV) in combination with anti-VEGF.
• Thermal Laser Photocoagulation: Suitable only for extrafoveal or juxtafoveal membranes (not subfoveal), as direct laser application to the fovea causes dense central scotoma.
• Subretinal Drug Delivery: Emerging surgical platforms (OcuSense, Orbit Biomedical) allow single-site delivery of anti-VEGF agents or gene therapy vectors directly beneath the macula, potentially offering sustained drug release without recurrent injections.
• Gene Therapy (Investigational): Subretinal delivery of AAV vectors encoding anti-VEGF proteins (e.g., RGX-314, ADVM-022) is in Phase II/III trials for nAMD, aiming for durable treatment after a single surgical procedure.
• Stem Cell and RPE Replacement Therapy (Experimental): Transplantation of iPSC-derived RPE patches beneath the macula is being investigated in clinical trials as a restorative approach to AMD.